Health & Biotech
Dimerix’s flags acceleration of Phase 3 trials for its COVID-19 treatment in Europe
Health & Biotech
ASX Cannabis Stocks: Creso pops on 450pc annual revenue increase
Health & Biotech
ASX Health Stocks: Hydrix implants world’s first Guardian heart attack alert system
Health & Biotech
Apiam is staying busy in M&A as it builds a dominant regional vet network – here’s how the numbers stack up
Health & Biotech
Dr Boreham’s Crucible: Who’s winning and losing in the life sciences IPO Olympiad?
Health & Biotech
ScoPo’s Powerplays: Solid earnings for health stocks all round, but price action stays with larger caps
Health & Biotech
A busy Q4 shows how Incannex Healthcare is laying the foundations for its clinically backed global growth strategy
Health & Biotech
Creso Pharma subsidiary plans to introduce new lines of super-potent pot
Health & Biotech
Prescient Therapeutics finished the June quarter stronger than ever
Health & Biotech
InteliCare targeting expansion as quarterly sales revenue rises 69%
Health & Biotech
PharmAust makes progress in the quarter as it lays the foundation for commercialisation
Health & Biotech
Opyl shares bounce on Q4 trading update with key revenue drivers in place for FY22
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.